85 related articles for article (PubMed ID: 11220526)
1. Do sulfonylurea drugs increase the risk of cardiac events?
Bell DS
CMAJ; 2006 Jan; 174(2):185-6. PubMed ID: 16415463
[No Abstract] [Full Text] [Related]
2. Cardiovascular Benefits of Potassium-Enriched Salt Substitution: Promises and Challenges of Secondary Analyses.
Tu W; Agarwal R
Hypertension; 2024 May; 81(5):1041-1043. PubMed ID: 38630800
[No Abstract] [Full Text] [Related]
3. Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.
Azim S; Baker WL; White WB
Curr Cardiol Rep; 2014 Nov; 16(11):541. PubMed ID: 25303895
[TBL] [Abstract][Full Text] [Related]
4. Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids.
Trevaskis JL; Mack CM; Sun C; Soares CJ; D'Souza LJ; Levy OE; Lewis DY; Jodka CM; Tatarkiewicz K; Gedulin B; Gupta S; Wittmer C; Hanley M; Forood B; Parkes DG; Ghosh SS
PLoS One; 2013; 8(10):e78154. PubMed ID: 24167604
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targets to reduce cardiovascular disease in type 2 diabetes.
DeSouza C; Fonseca V
Nat Rev Drug Discov; 2009 May; 8(5):361-7. PubMed ID: 19404311
[TBL] [Abstract][Full Text] [Related]
6. Myocardial glucose utilisation in type II diabetes mellitus patients treated with sulphonylurea drugs.
Yokoyama I; Inoue Y; Moritan T; Ohtomo K; Nagai R
Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):703-8. PubMed ID: 16528523
[TBL] [Abstract][Full Text] [Related]
7. ATP-sensitive K+ channels and insulin secretion: their role in health and disease.
Ashcroft FM; Gribble FM
Diabetologia; 1999 Aug; 42(8):903-19. PubMed ID: 10491749
[No Abstract] [Full Text] [Related]
8. Cardiovascular effects of sulphonylurea derivatives.
Smits P
Diabetologia; 1997 Jul; 40 Suppl 2():S160-1. PubMed ID: 9248730
[No Abstract] [Full Text] [Related]
9. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview.
Beck-Nielsen H; Hother-Nielsen O; Pedersen O
Diabet Med; 1988 Oct; 5(7):613-20. PubMed ID: 2975544
[No Abstract] [Full Text] [Related]
10. [Pharmacology of glimepiride].
Satoh Y
Nihon Rinsho; 1997 Nov; 55 Suppl():147-51. PubMed ID: 9434459
[No Abstract] [Full Text] [Related]
11. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels.
Ashcroft FM; Gribble FM
J Diabetes Complications; 2000; 14(4):192-6. PubMed ID: 11004427
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular effects of sulphonylureas: role of K(ATP) channels.
Howes LG
Diabetes Obes Metab; 2000 Apr; 2(2):67-73. PubMed ID: 11220526
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
